Wnt/beta-catenin inhibitor-eluting endovascular stent
View Patent ↗A product comprising a stent for a human blood vessel which comprises (i) a scaffold which is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/p-catenin pathway, or (ii) a scaffold coated with a polymer, which polymer is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/p-catenin pathway, and methods of use to reduce the risk of restenosis.
1. A product comprising a stent for a human blood vessel which comprises (i) a scaffold coated with a polymer, which polymer is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/β-catenin pathway, or (ii) a scaffold which is impregnated with, adsorbed with, or coated with, an inhibitor of a Wnt/β-catenin pathway, wherein the inhibitor comprises
2. The product of claim 1 , wherein the stent is a shaped to be suitable as an endovascular stent.
3. The product of claim 1 , wherein at least 50% of the inhibitor of a Wnt/β-catenin pathway elutes from the stent.
4. The product of claim 1 , wherein at least 90% of the inhibitor of a Wnt/β-catenin pathway elutes from the stent over a time period of 1 to 150 days.
5. The product of claim 1 , wherein the stent comprises a scaffold impregnated with, adsorbed with, or coated with, an inhibitor of a Wnt/β-catenin pathway.
6. The product of claim 1 , wherein the stent comprises a scaffold coated with a polymer impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/β-catenin pathway.
7. The product of claim 6 , wherein the inhibitor of a Wnt/β-catenin pathway is adsorbed within the polymer and/or adsorbed to a surface of the polymer.
8. The product of claim 6 , wherein the inhibitor of a Wnt/β-catenin pathway is coated on the polymer.
9. The product of claim 6 , wherein the polymer is not prothrombotic.
10. The product of claim 6 , wherein the polymer comprises one or more of poly(n-butyl methacrylate), poly(ethylene-co-vinyl acetate), poly(styrene-b-isobutylene-b-styrene) or poly(vinylidene fluoride-co-hexafluoropropylene).
11. The product of claim 6 , wherein the polymer comprises phosphorylcholine.
12. The product of claim 1 , wherein the polymer is biodegradable.
13. The product of claim 1 , wherein the stent is bioresorbable.
14. A method for performing an angioplasty in a mammalian subject comprising surgically inserting the stent of claim 1 into the a vascular vessel and expanding the stent therein so as perform the angioplasty.
15. A method for reducing restenosis in a vascular vessel at risk for restenosis of a mammalian subject, comprising surgically inserting the stent of claim 1 into the lumen of the vascular vessel at the site deemed at risk of restenosis, so as to reduce the risk of restenosis.
16. The method of claim 14 , wherein the vascular vessel is not a CNS vascular vessel.
17. The method of claim 14 , wherein the vascular vessel is a coronary vascular vessel.
18. The method of claim 14 , wherein the subject has atherosclerotic disease of the vascular vessel.
19. The method of claim 14 , wherein the subject has undergone an angioplasty of the vascular vessel.